Armistice Capital LLC Reduces Position in Supernus Pharmaceuticals, Inc. $SUPN

Armistice Capital LLC reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,764,000 shares of the specialty pharmaceutical company’s stock after selling 72,000 shares during the quarter. Supernus Pharmaceuticals comprises about 1.6% of Armistice Capital LLC’s portfolio, making the stock its 7th biggest position. Armistice Capital LLC owned 4.82% of Supernus Pharmaceuticals worth $137,371,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Torren Management LLC bought a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth $49,000. EverSource Wealth Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at about $51,000. Smartleaf Asset Management LLC lifted its stake in Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 268 shares during the period. Hantz Financial Services Inc. grew its holdings in Supernus Pharmaceuticals by 73.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 458 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth approximately $55,000.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $43.58 on Thursday. Supernus Pharmaceuticals, Inc. has a 52 week low of $30.83 and a 52 week high of $59.68. The company has a 50 day moving average price of $48.27 and a 200 day moving average price of $49.51. The firm has a market cap of $2.53 billion, a PE ratio of -85.45, a price-to-earnings-growth ratio of 0.93 and a beta of 0.55.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on SUPN shares. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Craig Hallum set a $65.00 price target on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Finally, Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 23rd. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $62.17.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.